Neutral<\/p>\n
-0.5%<\/p>\n
Upcoming presentations at major healthcare investor conferences in May and June 2026.<\/p>\n
Apr 15<\/p>\n
Earnings date set<\/a><\/p>\n Neutral<\/p>\n -2.4%<\/p>\n Scheduled first quarter 2026 results release and conference call details.<\/p>\n Apr 06<\/p>\n Leadership change<\/a><\/p>\n Positive<\/p>\n +5.0%<\/p>\n Appointment of new Chief R&D Officer to guide clinical development and pipeline.<\/p>\n Mar 04<\/p>\n Equity inducement grants<\/a><\/p>\n Neutral<\/p>\n -1.4%<\/p>\n Issuance of 65,850 RSUs to new employees under inducement plan.<\/p>\n Feb 26<\/p>\n Earnings and update<\/a><\/p>\n Positive<\/p>\n +4.6%<\/p>\n Strong 2025 ORLADEYO revenue growth, record operating profit, and maintained 2026 guidance.<\/p>\n Pattern Detected<\/p>\n Across recent events, price moves have generally aligned with the perceived tone of the news, with positive operational updates and earnings followed by positive reactions.<\/p>\n Recent Company History<\/p>\n Over the last few months, BioCryst has focused on strengthening its commercial base and governance. A February 2026 earnings update highlighted strong ORLADEYO revenue growth and maintained 2026 guidance, with a positive price reaction. Subsequent filings detailed equity plan changes and insider transactions. A new Chief R&D Officer was appointed in early April 2026, and conference appearances and an upcoming Q1 results date were announced. Today\u2019s European licensing agreement for navenibart adds a non-dilutive capital inflow and extends that strategic trajectory in HAE.<\/p>\n \n This announcement grants Neopharmed Gentili\u2019s Irish affiliate exclusive European rights to navenibart for hereditary angioedema, providing BioCryst with $70M upfront, up to $275M in milestones, and 18%\u201330% royalties. Navenibart remains in a Phase 3 program targeting a US filing by the end of 2027. In context of prior strong ORLADEYO performance and ongoing R&D investments, investors may watch clinical progress, regulatory timelines, and execution by the European partner.\n <\/p>\n hereditary angioedema<\/p>\n medical<\/p>\n “exclusive license to commercialize navenibart for hereditary angioedema in Europe”<\/p>\n A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood\u2011control protein is missing or not working. Attacks can be unpredictable and sometimes life\u2011threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.<\/p>\n plasma kallikrein inhibitor<\/p>\n medical<\/p>\n “Navenibart is an investigational, long-acting plasma kallikrein inhibitor.”<\/p>\n A plasma kallikrein inhibitor is a drug that blocks a specific blood protein (plasma kallikrein) involved in processes like swelling, inflammation, and leaking blood vessels; think of it as turning off a faucet that fuels sudden internal swelling. For investors, these drugs matter because their ability to prevent or treat conditions driven by that protein \u2014 and their safety, regulatory approval, and market alternatives \u2014 strongly affect potential sales, development costs, and competitive value.<\/p>\n AI-generated analysis. Not financial advice.<\/p>\n 05\/04\/2026 – 07:00 AM<\/p>\n \u2014 BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe \u2014<\/p>\n \u2014 BioCryst to receive $70M upfront, up to $275M in future regulatory and sales milestone payments, and royalties on sales ranging from 18 to 30 percent \u2014<\/p>\n \u2014 Agreement builds upon prior agreement between the two companies for\u00a0sale of European ORLADEYO\u00ae business to Neopharmed Gentili in 2025 \u2014<\/p>\n \u2014 Navenibart Phase 3 program in HAE on track for US regulatory filing by end of 2027 \u2014<\/p>\n RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc.<\/a> (Nasdaq:BCRX) today announced that it entered into a license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema (HAE) in Europe. In exchange, BioCryst will receive $70M upfront and will be eligible to receive up to $275M in future regulatory and sales milestone payments. BioCryst will also receive tiered royalties on net sales ranging from 18% to 30%.<\/p>\n Navenibart is an investigational, long-acting plasma kallikrein inhibitor. BioCryst is conducting a Phase 3 clinical program of navenibart in hereditary angioedema. The program is on track to support regulatory filing by the end of 2027.<\/p>\n Transaction Rationale<\/p>\n Builds on an existing relationship with a proven partner with deep regional expertise. Neopharmed Gentili operates the European commercial infrastructure originally built by BioCryst for ORLADEYO\u00ae (berotralstat), creating high confidence in execution continuity and performance to improve patient welfare.Optimizes commercial focus and portfolio coordination. Dedicated commercial organizations in the U.S. and Europe will each lead the commercialization of ORLADEYO and navenibart in their respective territories, enhancing launch readiness, brand coherence, and patient access.Strengthens financial position. The transaction delivers near-term capital to strengthen BioCryst\u2019s balance sheet, while retaining meaningful upside through milestones and royalties, providing optionality for deployment of capital to other value accretive opportunities. <\/p>\n \u201cWe are excited to partner with Neopharmed Gentili once again to help bring innovative medicines to patients living with HAE in Europe. This deal enables both companies to build upon the strong foundation of ORLADEYO and leverages Neopharmed Gentili\u2019s expertise in Europe to drive continued execution and positive patient outcomes in the territory. This transaction is further illustration of our commitment to focus our business and continue to execute our strategy of delivering commercial excellence in the US while putting the business in a position of financial strength,\u201d said Charlie Gayer, President and Chief Executive Officer of BioCryst.<\/p>\n \u201cWe are proud to further strengthen and expand our collaboration with BioCryst Pharmaceuticals through this strategic agreement for navenibart, reinforcing a partnership grounded in a shared commitment to delivering meaningful impact for people living with hereditary angioedema,\u201d said Alessandro Del Bono, Chief Executive Officer of Neopharmed Gentili. \u201cThis agreement underscores our steadfast dedication to advancing therapeutic innovation in areas of significant unmet medical need, builds upon the strong expertise we have established in Europe in HAE, and further accelerates our long-term growth trajectory\u2013consolidating our position as a leading European company in the field of rare diseases.\u201d<\/p>\n About BioCryst Pharmaceuticals <\/p>\n BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (\u201cHAE\u201d) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO\u00ae (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com<\/a> or follow us on LinkedIn<\/a>.<\/p>\n Forward-Looking Statements <\/p>\n This press release contains forward-looking statements, including statements regarding future results, performance or achievements; expectations regarding pipeline development, including timing for regulatory filings for navenibart; anticipated approval and commercialization of navenibart; potential future milestone payments or royalties; our ability to successfully execute future product launches; statements as to the expected benefits of the transaction, including future financial and operating results; plans for deployment of capital; positive patient outcomes; and BioCryst\u2019s plans, objectives, expectations, intentions, growth strategies and other statements that are not historical facts. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst\u2019s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst\u2019s ability to successfully progress its pipeline development plans, including meeting the expected timelines; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; the results of BioCryst\u2019s partnerships with third parties may not meet BioCryst\u2019s current expectations, including that our partners may fail to reach performance milestones or achieve certain royalty thresholds under our license agreements; legislative, regulatory and economic developments affecting BioCryst\u2019s and Neopharmed Gentili\u2019s businesses; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management\u2019s expected ranges. This list is not exclusive. To see a more comprehensive list of risks, please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst\u2019s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst\u2019s projections and forward-looking statements.<\/p>\n BCRXW<\/p>\n Contact:<\/p>\n Investors: Media: \n FAQ\n <\/p>\n What did BioCryst (BCRX) agree with Neopharmed Gentili on May 4, 2026?<\/p>\n \n BioCryst granted Neopharmed Gentili\u2019s Irish affiliate exclusive European rights to navenibart for HAE, for $70M upfront plus milestones and royalties, according to BioCryst.\n <\/p>\n How much can BioCryst (BCRX) earn from the navenibart Europe license?<\/p>\n \n BioCryst will receive $70M upfront and is eligible for up to $275M in regulatory and sales milestones, plus 18%\u201330% royalties, according to BioCryst.\n <\/p>\n When is BioCryst (BCRX) planning a regulatory filing for navenibart?<\/p>\n \n BioCryst targets a U.S. regulatory filing by the end of 2027 for navenibart, with Phase 3 underway to support that filing, according to BioCryst.\n <\/p>\n What rights does Neopharmed Gentili obtain for navenibart in Europe?<\/p>\n \n Neopharmed Gentili\u2019s Irish affiliate obtains exclusive commercialization rights for navenibart in Europe, building on its existing ORLADEYO commercial operations, according to BioCryst.\n <\/p>\n How does the navenibart deal affect BioCryst\u2019s finances and focus?<\/p>\n \n The deal provides near\u2011term capital to strengthen BioCryst\u2019s balance sheet and retains upside via milestones and royalties, while focusing U.S. commercialization on ORLADEYO, according to BioCryst.\n <\/p>\n","protected":false},"excerpt":{"rendered":"BioCryst (Nasdaq: BCRX) granted an Irish affiliate of Neopharmed Gentili an exclusive license to commercialize navenibart for hereditary…\n","protected":false},"author":2,"featured_media":30736,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[20809,20804,20803,4,20808,20807,20806,20805,20810],"class_list":{"0":"post-30735","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-europe","8":"tag-70m-upfront","9":"tag-bcrx","10":"tag-biocryst","11":"tag-europe","12":"tag-europe-licensing-deal","13":"tag-hereditary-angioedema","14":"tag-navenibart","15":"tag-neopharmed-gentili","16":"tag-royalties"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/30735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/comments?post=30735"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/30735\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media\/30736"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media?parent=30735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/categories?post=30735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/tags?post=30735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
investorrelations@biocryst.com<\/p>\n
media@biocryst.com<\/p>\n![\"\"](\"https:\/\/www.europesays.com\/europe\/wp-content\/uploads\/2026\/05\/1777903884_805_ti.gif\"\/)
![\"\"](\"https:\/\/www.europesays.com\/europe\/wp-content\/uploads\/2026\/05\/BioCryst-Pharmaceuticals-Inc-.png\")
<\/p>\n